Ocular immunology investigates the complex interplay between molecular mediators and immune cells responsible for maintaining ocular immune privilege, as ...

New phase 3 data showed that patients with primary immune thrombocytopenia saw improved disease control when ianalumab was added to Promacta (eltrombopag) treatment compared to Promacta alone. Data ...

More than half of patients in a Phase III clinical trial who received a limited course of the experimental monoclonal antibody ianalumab for primary immune thrombocytopenia (ITP), an autoimmune ...

The addition of ianalumab to eltrombopag significantly improved outcomes for patients with pretreated primary immune ...

Two years after this, Sakaguchi was able to link these discoveries. He proved that the Foxp3 gene governs the development of ...

ORLANDO -- Adding four monthly infusions of novel ianalumab helped adults with primary immune thrombocytopenia (ITP) achieve durable disease control in the second-line setting while stopping daily ...

More than half of patients in a Phase III clinical trial who received a limited course of the experimental monoclonal ...

Patients with immune thrombocytopenia (ITP) who received a first-in-class investigational drug in addition to standard ...

Multigene families are at the core of immune system complexity, shaping how organisms sense, respond to, and remember infection. Gene duplication, ...

Patients with immune thrombocytopenia (ITP) who received a first-in-class investigational drug in addition to standard therapy went longer without a bleeding episode that needed urgent treatment or ...

Ianalumab (9 mg/kg) plus eltrombopag extended ITP disease control by 45% with patients maintaining disease control 2.8 times longer than with placebo plus eltrombopag1,262% of patients treated with ...